Trial Magpie

Patient-friendly clinical trial database built for patients.

Free to use, no personal data collected.

Launched Mar 16 2026

[Trial Magpie @TrialMagpie]

Introducing TrialMagpie:

Most patients who could benefit from a clinical trial never find one. We built TrialMagpie to change that.

Patient-friendly search across thousands of active US studies, filtered by condition, phase & location, and tailored to YOU.

Private by design, no saved data.

https://t.co/zgFmh4iOrP

#clinicaltrials #patientadvocacy

[Trial Magpie @TrialMagpie]

TrialMagpie CT Spotlight — REACT-AF (NCT05836987)

Can Apple Watch-guided anticoagulation prevent strokes just as well as daily blood thinners while reducing bleeding risk and drug burden?

Most people with atrial fibrillation take blood thinners every single day for the rest of their lives. Johns Hopkins is testing whether your Apple Watch can tell you when you actually need it.

AFib is the leading cause of stroke from a heart arrhythmia. Direct oral anticoagulants (DOACs) dramatically reduce that risk, but they come with real burdens: daily pills, bleeding risk, drug interactions, and expense. And for the millions with paroxysmal AFib, where episodes come and go, patients are taking blood thinners around the clock even when their heart is in perfectly normal rhythm.

REACT-AF is testing a different approach. Participants wear an AF-sensing smartwatch (Apple Watch + the REACT-AF app) that passively monitors heart rhythm 24/7. When an AF episode is detected, a one-month DOAC course is triggered. The control group stays on its current regimen.

If it works, this could fundamentally change how millions of AFib patients manage their stroke risk. The watch becomes the prescription.

The Phase 3 trial is currently enrolling 5,350 adults aged 22–85 with paroxysmal or persistent AFib and low-to-moderate stroke risk across 91 sites.

https://t.co/3UvPtIxLf2
https://t.co/fmlBBW3ppj

Led by PIs @PassmanRod and Dr. Dan Hanley @JohnsHopkins @NorthwesternU

#clinicaltrials #TrialMagpieSpotlight #AFib #AtrialFibrillation #HeartHealth #DigitalHealth

[Trial Magpie @TrialMagpie]

@NIH In the AI age, better non-invasive diagnostics may be on the horizon, and in some cases could rival or even replace tissue biopsy. We're here for it

[Trial Magpie @TrialMagpie]

TrialMagpie CT Spotlight -- Neoadjuvant Ficerafusp Alfa + Pembrolizumab in Resectable HNSCC -- NCT07465276

Pembrolizumab is standard of care for PD-L1-positive head and neck cancer. But tumors use TGF-β to suppress immune activity, which pembrolizumab doesn't block.

Ficerafusp alfa is an experimental antibody that blocks two proteins at once: EGFR, which drives tumor growth, and TGF-β, which tumors use to "hide from the immune system."

Dana-Farber is now testing that combination as neoadjuvant therapy in patients with resectable, locally advanced, PD-L1-positive HNSCC.
Patients receive two cycles before proceeding to surgical resection.

The trial is enrolling 32 participants and was posted today.

For context: Bicara Therapeutics is also running an ongoing Phase 2/3 study of ficerafusp alfa + pembrolizumab in recurrent or metastatic HNSCC (NCT06788990), a larger randomized trial in patients who are not surgical candidates.

https://t.co/tL7EqGaaMC
https://t.co/CFyXVudzmR

Led by @HeadNeckMD @DanaFarber @BrighamWomens and collaborators @BicaraTx @Merck

#clinicaltrials #TrialMagpieSpotlight #HeadAndNeckCancer #HNSCC

[Trial Magpie @TrialMagpie]

TrialMagpie CT Spotlight — REVEAL: ION582 for Angelman Syndrome (NCT06914609)

Angelman syndrome is a rare genetic disorder caused by the loss of function of the UBE3A gene. It affects roughly 1 in 15,000 people and is characterized by developmental delay, limited or absent speech, seizures, and movement difficulties. There are no approved treatments to address the underlying cause.

Here's the catch: a working copy of the gene exists on the paternal chromosome. But, in neurons, it's actively suppressed.

ION582, developed by Ionis Pharmaceuticals, is an antisense oligonucleotide designed to unmute the paternal copy. The concept isn't replacing a broken gene; it's unsilencing one that was always working.

Ionis has had success with antisense technology before. The company developed nusinersen (SPINRAZA), the first effective treatment for spinal muscular atrophy. REVEAL is the Phase 3 trial in Angelman — enrolling children and adults ages 2 to 50, at 14 US sites including Boston Children's, Rady Children's, Cedars-Sinai, and Children's National.

Phase 2 results showed meaningful improvements in communication, motor function, development, and seizure frequency.

https://t.co/XZ7IT43Z5f
https://t.co/h1S5Wv2ai4

@ionispharma @angelman

#clinicaltrials #TrialMagpieSpotlight #AngelmanSyndrome #RareDisease

[Trial Magpie @TrialMagpie]

@WomenAs1 @Drroxmehran The exclusion criteria issue you highlighted is under appreciated, and not just because of lack of equity. Guidelines created on homogenous patient populations are rarely suitable for the RW. Thank you for bringing attention to this

[Trial Magpie @TrialMagpie]

Bringing trials into community settings matters A LOT. Most patients never make it to a major academic centers. We think awareness is the other side of the coin. Patients need to know trials exist before they can even ask about them, a lot of physicians don't bring them up of their own accord.

Can't forget about language access too. Spanish-speaking patients are chronically underrepresented in trials and most tools still don't serve them well

[Trial Magpie @TrialMagpie]

Wrote something for anyone navigating a difficult diagnosis (or their loved ones). Whether options are limited, or if you are wondering if there are other alternatives:

Why your doctor might not mention clinical trials, and how you can start the conversation: https://t.co/OkrrWLS8Xr

#rarediseases #patientadvocacy #clinicaltrials

[Trial Magpie @TrialMagpie]

@IMFmyeloma @Bethfaiman @jmikhaelmd What the IMF has built is special. Free, always available, no barriers. We agree that informed patients make better decisions and commend you for your sustained efforts in patient advocacy

[Trial Magpie @TrialMagpie]

TrialMagpie CT Spotlight — NCT05407636

Would you explore other options if your condition required eye injections for the rest of your life? AbbVie is testing efficacy of a single procedure in this Phase 3 trial.

Neovascular (wet) AMD is the leading cause of severe vision loss in adults over 50. The current standard of care works, but it requires injections directly into the eye every 4 to 12 weeks.

The gene therapy, ABBV-RGX-314 is designed to replace those repeat injections with a single subretinal procedure. The therapy uses an AAV8 vector to deliver genetic info directly to the retina, prompting the eye to produce its own anti-VEGF protein indefinitely.

The Phase 3 compares one-time gene therapy (at two dose levels) against ongoing EYLEA (aflibercept) injections directly into the eye.

Led by @abbvie

https://t.co/M1mJd75X5B https://t.co/nvlRq4lObx

#clinicaltrials #TrialMagpieSpotlight #GeneTherapy #Ophthalmology

[Trial Magpie @TrialMagpie]

The words "randomized, double-blind, placebo-controlled, multi-center" are often first things on a clinical trial listing. Here's what they all mean:

https://t.co/0neAs9ayZd

#PatientAdvocacy #PatientEducation #HealthLiteracy

[Trial Magpie @TrialMagpie]

@OncLive @SagarLonialMD @WinshipAtEmory @EmoryMedicine For myeloma*

[Trial Magpie @TrialMagpie]

@OncLive @SagarLonialMD @WinshipAtEmory @EmoryMedicine Great overview, thank you Dr. Lonial. Seems like CELMoDs are one of the most active areas in myeloma research. By our count, there are ~15 active iberdomide trials currently enrolling in the US

[Trial Magpie @TrialMagpie]

TrialMagpie CT Spotlight — Ivermectin Combined With Immune Checkpoint Inhibition in Cancer (ICONIC)

In 2023, researchers surveyed cancer patients in Ecuador and 19% were already taking a controversial anti-parasitic, ivermectin, alongside their cancer treatment.

Now researchers at the University of Florida are putting ivermectin to the test in a Phase 2 study in adults with solid tumors.

The hypothesis: ivermectin may sensitize tumors to immunotherapy through multiple pathways, including WNT/β-catenin signaling and immune modulation.

Would love to hear thoughts: does ivermectin's reputation make you more or less skeptical of this trial?

Led by Dr. Leighton Elliott @UF @UFHealth

https://t.co/rYCnhEVw8c https://t.co/ycj5v4Nx2V

#clinicaltrials #TrialMagpieSpotlight #Ivermectin

[Trial Magpie @TrialMagpie]

@DFCI_BreastOnc @esalehiDNP Cold capping has a strong track record with taxanes, looking forward to seeing the data on its use with newer agents. Great to see this being studied

[Trial Magpie @TrialMagpie]

@OncoDailyIO @DukeCancer Saw that the BBOpCo trial from this lab stopped recruiting back in Feb (or at least that's when https://t.co/4ns5ZyuO6o was updated). Keeping our eyes out for results following the data presentation at AACR!

[Trial Magpie @TrialMagpie]

TrialMagpie CT Spotlight — mRNA CAR-T for Myasthenia Gravis (NCT06799247)

CAR-T therapy was designed to hunt down and destroy cancer cells. Researchers are now turning it on the cells causing an autoimmune disease.

Myasthenia gravis is driven by antibodies that block the connection between nerve and muscle. Those antibodies are made by plasma cells that express BCMA, which is the same target used in CAR-T therapies for multiple myeloma.

Descartes-08 (Cartesian Therapeutics) uses mRNA instead of a viral vector, so the CAR expression is temporary. Think of it as a controlled pulse to reset the immune system, not a permanent modification. Phase 3 AURORA Study is now enrolling at 25 US sites.

Led by @CartesianTX

https://t.co/fTppqYLspZ https://t.co/WzrSfMH5MC

#clinicaltrials #TrialMagpieSpotlight #MyastheniaGravis #raredisease @MyastheniaOrg

[Trial Magpie @TrialMagpie]

Very true and you're highlighting one of the harder problems we work through every day. The lack of standardization around drug interventions (and really every metric) on https://t.co/QsPAtODZjL is real. The same compound can appear dozens of ways across trials, with no consistent naming, no enforced vocabulary. We are doing our best to consistently refine and improve to give people the power to browse open clinical trials

[Trial Magpie @TrialMagpie]

Clinical trials are written for researchers. We're rewriting them for patients.

Plain English (or Spanish). Smart search. No login required. Updated daily.

TrialMagpie is live.

Read the introductory announcement here:
https://t.co/0v1hJ66G8k

#patientaccess #clinicaltrials #patientadvocacy

[Trial Magpie @TrialMagpie]

TrialMagpie CT Spotlight — Ride-On Toy Cars for Children With Hemiplegia (NCT06579027)

Researchers are giving kids with hemiplegia (paralysis or weakness on one side of the body) joystick-powered ride-on toy cars and are calling it therapy.

For children ages 3–8 with hemiplegia, learning to steer a toy car trains the weaker arm to engage. Parents and caregivers co-deliver the sessions at home, guided by researchers at UConn.

The hypothesis: making therapy feel like play may lead to improved arm function and higher chances kids will stick with it.

Led by Dr. Sudha Srinivasan at @UConn

https://t.co/TT83y3iWTR | https://t.co/8ilUN85mLU

#TrialMagpieSpotlight #PedsRehab #CerebralPalsy